Bacterin Announces Public Offering of Common Stock BELGRADE, MT

Bacterin Announces Public

Offering of Common Stock

BELGRADE, MT, July 31, 2014 -- Bacterin

International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medical applications,

today announced that it intends to offer shares of its common stock and warrants to purchase common stock in an underwritten public

offering pursuant to an effective shelf registration statement.

Net proceeds from the offering are expected

to be used for working capital and general corporate purposes including the continued expansion of the company's sales force

and increasing inventory levels to support anticipated future growth.

Northland Securities, Inc. is acting as the

sole book-running manager for the offering. Copies of the prospectus and prospectus supplement relating to the shares of common

stock and warrants to purchase common stock offered in this offering may be obtained by contacting Northland Securities, Inc. at

45 South Seventh Street, Suite 2000, Minneapolis, MN 55402, or by calling toll free 800-851-2920, or by e-mail at apafko@northlandcapitalmarkets.com.

The offering is being conducted pursuant to

an effective shelf registration statement on file with the Securities and Exchange Commission. A prospectus supplement relating

to the offering will be filed with the Securities and Exchange Commission.

This press release shall not constitute an offer

to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or

other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under

the securities laws of any such state or other jurisdiction.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE

MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. These products are used

in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot

and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops,

employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking

This news release contains certain disclosures

that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that

are subject to significant risks and uncertainties, including statements regarding our expectations with respect to the completion

and anticipated proceeds of the public offering. Forward-looking statements include statements that are predictive in nature,

that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts,"

"expects," "anticipates," "intends," "plans," "believes," "estimates,"

"projects," "forecasts," "strategy," "will," "goal," "target," "prospects,"

"potential," "optimistic," "confident," "likely," "probable" or similar expressions

or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these

statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of

important factors, including, among others: the Company's ability to meet its existing and anticipated contractual obligations,

including financial covenant and other obligations contained in the Company's secured lending facility; the Company's

ability to manage cash flow and achieve profitability; the Company's ability to remain listed on the NYSE MKT; the Company's

ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual

property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay

and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands

and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the

Company's ability to successfully conclude government investigations; the impact of changes in market, legal and regulatory

conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors

are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors."

The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or

circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Northland Capital Markets is the trade

name for certain capital markets and investment banking services of Northland Securities, Inc., member FINRA/SIPC.